Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
10:30am, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
06:30am, Thursday, 02'nd Jun 2022
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
11:30am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
07:30am, Wednesday, 01'st Jun 2022
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
10 Biggest Price Target Changes For Tuesday
12:44pm, Tuesday, 10'th May 2022 Benzinga
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.
Mizuho raised the price target for Amgen Inc. (NASDAQ: AMGN) from
Annexon Biosciences to Participate in Upcoming May Investor Conferences
10:30am, Thursday, 05'th May 2022 GlobeNewswire Inc.
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
Annexon Biosciences to Participate in Upcoming May Investor Conferences
06:30am, Thursday, 05'th May 2022
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical c
What Are Penny Stocks? What You Need to Know and 3 to Watch
07:41pm, Wednesday, 20'th Apr 2022 PennyStocks
Check these three penny stocks out for your watchlist
The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
What Are Penny Stocks? What You Need to Know and 3 to Watch
03:41pm, Wednesday, 20'th Apr 2022
Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
10:30am, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
Topline efficacy and safety data expected in first half of 2023 Topline efficacy and safety data expected in first half of 2023
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
10:30am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classic
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
09:01pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patie
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patient
Annexon Biosciences GAAP EPS of -$0.97 misses by $0.05 (NASDAQ:ANNX)
10:05pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Annexon Biosciences press release (ANNX): Q4 GAAP EPS of -$0.97 misses by $0.05.Cash and operating runway: Cash and cash equivalents and short-term investments were $242.7 million as…
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023
